Takeaways from the most recent news in the technology and policies shaping healthcare.
The money moving through health tech: venture rounds, M&A, IPOs, and the financial health of the companies and systems behind care.
AstraZeneca's oral GLP-1 drug showed promise in mid-stage obesity and diabetes trials, but its standing against rival pills remains unclear.
Why it matters: An effective GLP-1 pill could broaden access to weight-loss and diabetes treatment and intensify competition in a market headed past $100 billion.
Incyte is acquiring Vega Therapeutics for $1.25 billion to gain a late-stage von Willebrand disease drug as patent expiration looms for its top product, Jakafi.
Why it matters: The deal shows how biopharma companies race to backfill pipelines and diversify ahead of major patent cliffs.
GSK is acquiring Nuvalent for $10.6 billion to add late-stage targeted lung cancer drugs, the latest in a run of biopharma deals.
Why it matters: The deal shows how big drugmakers are spending billions on precision oncology to refill pipelines ahead of patent cliffs.
Gilead and Merck reported one trial win and one failure the same week, as AstraZeneca advanced a GLP-1 pill and GSK announced a $10.6 billion cancer acquisition.
Why it matters: Late-stage trial outcomes and multibillion-dollar deals from pharma's biggest players shape which therapies reach patients and where investor capital flows.
GSK will acquire Nuvalent for $10.6 billion, gaining two near-commercial precision drugs for non-small cell lung cancer that are now under FDA review.
Why it matters: The deal underscores how big pharma is paying premium prices for late-stage precision oncology assets to refill pipelines and accelerate revenue.
R1 RCM named former Humana CTO Eric Tagliere as chief information officer to lead its global technology organization.
Why it matters: R1 processes billing for many U.S. health systems, so its technology leadership shapes how providers get paid amid mounting margin pressure.